Organogenesis Holdings Inc. (ORGO)
NASDAQ: ORGO · Real-Time Price · USD
2.390
-0.040 (-1.65%)
At close: Jul 24, 2026, 4:00 PM EDT
2.385
-0.005 (-0.21%)
After-hours: Jul 24, 2026, 7:34 PM EDT
Organogenesis Holdings Revenue
Organogenesis Holdings had revenue of $37.23M in the quarter ending March 31, 2026, a decrease of -57.06%. This brings the company's revenue in the last twelve months to $514.70M, up 12.19% year-over-year. In the year 2025, Organogenesis Holdings had annual revenue of $564.17M with 17.04% growth.
Revenue (ttm)
$514.70M
Revenue Growth
+12.19%
P/S Ratio
0.60
Revenue / Employee
$602,698
Employees
854
Market Cap
307.53M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 564.17M | 82.13M | 17.04% |
| Dec 31, 2024 | 482.04M | 48.90M | 11.29% |
| Dec 31, 2023 | 433.14M | -17.75M | -3.94% |
| Dec 31, 2022 | 450.89M | -16.47M | -3.52% |
| Dec 31, 2021 | 467.36M | 129.06M | 38.15% |
| Dec 31, 2020 | 338.30M | 77.32M | 29.63% |
| Dec 31, 2019 | 260.98M | 67.53M | 34.91% |
| Dec 31, 2018 | 193.45M | -5.06M | -2.55% |
| Dec 31, 2017 | 198.51M | 59.78M | 43.09% |
| Dec 31, 2016 | 138.73M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tilray Brands | 858.28M |
| Emergent BioSolutions | 676.80M |
| Evolus | 301.79M |
| Akebia Therapeutics | 232.40M |
| Canopy Growth | 203.89M |
| Kamada | 181.68M |
| Anika Therapeutics | 116.26M |
| SIGA Technologies | 93.78M |
ORGO News
- 16 days ago - Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026 - GlobeNewsWire
- 19 days ago - Organogenesis announces FDA acceptance of ReNu biologics license application - TheFly
- 19 days ago - Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis - GlobeNewsWire
- 5 weeks ago - Organogenesis Holdings Transcript: AGM 2026 - Transcripts
- 2 months ago - Organogenesis initiated with a Hold at Truist - TheFly
- 2 months ago - Organogenesis downgraded to Neutral from Buy at BTIG - TheFly
- 2 months ago - Organogenesis Holdings Earnings Call Transcript: Q1 2026 - Transcripts
- 2 months ago - Organogenesis Holdings Earnings release: Q1 2026 - Filings